Clinical trial
Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung…
NCT00003495 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003495 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Lung Cancer |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 7 |
| Start date | Mar 27, 1996 |
| Primary completion | Nov 4, 2003 |
| Completion | Nov 4, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: